Tectonic Therapeutic, Inc. (TECX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$20.07-4.84%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tectonic Therapeutic, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.393
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-5.168
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-5.315

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Progress Phase 2 readout for TX45 and advance TX2100 into clinical development	It aims to advance Phase 2 readout for TX45 and start clinical development of TX2100.	Intact	failure to achieve Phase 2 readout for TX45 or clinical start of TX2100 by 2028-Q4	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a recent 2026-09 press release. Management completed enrollment in the TX45 APEX Phase 2 trial and expects topline results early Q1 2027. TX2100 Phase 1a trial dosing completed with topline results expected by end Q3 2026; FDA cleared IND for Phase 1b and granted Fast Track designation. The clinical development trajectory is delivering with ongoing trials and regulatory progress. Delivery assessment Oct 24, 2026
Limit operating losses while advancing clinical programs	Management is focused on controlling expenses amid ongoing losses.	Intact	operating losses worsen beyond -$27.3M per quarter	Operating income: $-24.218M FY2026-Q2; GAAP. Published target: Operating losses not worsening beyond -$27.3M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-24,218,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b8609f75-f5c9-4be9-9192-2d4a889ab1ac. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated controlling operating expenses in 2 quarters, 2026-Q1 and 2026-Q2. R&D expenses were $20.9M in Q1 and $18.0M in Q2; G&A expenses were $6.4M and $6.2M respectively. Net loss decreased from $25.2M to $22.3M over these quarters. The trajectory shows limited progress in expense control amid ongoing net losses consistent with clinical-stage biotech operations. Delivery assessment Oct 24, 2026
Maintain cash runway through late 2028 to fund operations	Tectonic Therapeutic has a cash runway into late 2028 to fund clinical trials.	Intact	cash runway falls short of Q4 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-5.32

$-5.68 → $-5.32 · observed estimates

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-5.68	$0	9 / 8
2026-07-25	$-5.68	$0	9 / 8
2026-07-26	$-5.68	Unavailable	8 / 0
2026-07-27	$-5.68	$0	9 / 8
2026-07-28	$-5.68	$0	9 / 8
2026-07-29	$-5.68	Unavailable	8 / 0
2026-07-30	$-5.68	Unavailable	8 / 0
2026-07-31	$-5.68	$0	9 / 8
2026-08-01	$-5.68	Unavailable	8 / 0
2026-08-02	$-5.68	$0	9 / 8
2026-08-03	$-5.68	$0	9 / 8
2026-08-04	$-5.68	Unavailable	8 / 0
2026-08-05	$-5.68	Unavailable	8 / 0
2026-08-06	$-5.68	Unavailable	8 / 0
2026-08-08	$-5.68	Unavailable	8 / 0
2026-08-09	$-5.68	$0	9 / 8
2026-08-10	$-5.68	$0	9 / 8
2026-08-12	$-5.68	Unavailable	8 / 0
2026-08-13	$-5.68	Unavailable	8 / 0
2026-08-14	$-5.68	Unavailable	8 / 0
2026-08-15	$-5.68	Unavailable	8 / 0
2026-08-16	$-5.68	Unavailable	8 / 0
2026-08-17	$-5.68	Unavailable	8 / 0
2026-08-18	$-5.68	Unavailable	8 / 0
2026-08-19	$-5.68	Unavailable	8 / 0
2026-08-20	$-5.41	Unavailable	8 / 0
2026-08-21	$-5.41	Unavailable	8 / 0
2026-08-22	$-5.41	Unavailable	8 / 0
2026-08-23	$-5.41	Unavailable	8 / 0
2026-08-24	$-5.41	Unavailable	8 / 0
2026-08-25	$-5.41	Unavailable	8 / 0
2026-08-26	$-5.41	Unavailable	8 / 0
2026-08-27	$-5.41	Unavailable	8 / 0
2026-08-28	$-5.41	Unavailable	8 / 0
2026-08-29	$-5.41	Unavailable	8 / 0
2026-08-30	$-5.41	Unavailable	8 / 0
2026-08-31	$-5.41	Unavailable	8 / 0
2026-09-01	$-5.41	Unavailable	8 / 0
2026-09-02	$-5.41	Unavailable	8 / 0
2026-09-03	$-5.41	Unavailable	8 / 0
2026-09-04	$-5.41	Unavailable	8 / 0
2026-09-05	$-5.41	Unavailable	8 / 0
2026-09-06	$-5.41	Unavailable	8 / 0
2026-09-07	$-5.41	Unavailable	8 / 0
2026-09-08	$-5.41	Unavailable	8 / 0
2026-09-09	$-5.41	Unavailable	8 / 0
2026-09-10	$-5.41	Unavailable	8 / 0
2026-09-11	$-5.41	Unavailable	8 / 0
2026-09-12	$-5.41	Unavailable	8 / 0
2026-09-13	$-5.41	Unavailable	8 / 0
2026-09-14	$-5.41	Unavailable	8 / 0
2026-09-15	$-5.41	Unavailable	8 / 0
2026-09-16	$-5.41	Unavailable	8 / 0
2026-09-17	$-5.38	Unavailable	7 / 0
2026-09-18	$-5.38	Unavailable	7 / 0
2026-09-19	$-5.38	Unavailable	7 / 0
2026-09-20	$-5.38	Unavailable	7 / 0
2026-09-21	$-5.38	Unavailable	7 / 0
2026-09-22	$-5.38	Unavailable	7 / 0
2026-09-23	$-5.38	Unavailable	7 / 0
2026-09-24	$-5.38	Unavailable	7 / 0
2026-09-25	$-5.38	Unavailable	7 / 0
2026-09-26	$-5.38	Unavailable	7 / 0
2026-09-27	$-5.38	Unavailable	7 / 0
2026-09-28	$-5.38	Unavailable	7 / 0
2026-09-29	$-5.38	Unavailable	7 / 0
2026-09-30	$-5.38	Unavailable	7 / 0
2026-10-01	$-5.38	Unavailable	7 / 0
2026-10-02	$-5.38	Unavailable	7 / 0
2026-10-03	$-5.38	Unavailable	7 / 0
2026-10-04	$-5.38	Unavailable	7 / 0
2026-10-05	$-5.38	Unavailable	7 / 0
2026-10-06	$-5.38	Unavailable	7 / 0
2026-10-07	$-5.38	Unavailable	7 / 0
2026-10-08	$-5.38	Unavailable	7 / 0
2026-10-09	$-5.38	Unavailable	7 / 0
2026-10-10	$-5.38	Unavailable	7 / 0
2026-10-11	$-5.38	Unavailable	7 / 0
2026-10-12	$-5.38	Unavailable	7 / 0
2026-10-13	$-5.32	Unavailable	5 / 0
2026-10-14	$-5.32	Unavailable	5 / 0
2026-10-15	$-5.32	Unavailable	5 / 0
2026-10-16	$-5.32	Unavailable	5 / 0
2026-10-17	$-5.32	Unavailable	5 / 0
2026-10-18	$-5.32	Unavailable	5 / 0
2026-10-19	$-5.32	Unavailable	5 / 0
2026-10-20	$-5.32	Unavailable	5 / 0
2026-10-21	$-5.32	Unavailable	5 / 0
2026-10-22	$-5.32	Unavailable	5 / 0
2026-10-23	$-5.32	Unavailable	5 / 0
2026-10-24	$-5.32	Unavailable	5 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	0
2026-06-01	10	0
2026-07-01	10	0
2026-08-01	10	0
2026-09-01	10	0
2026-10-01	9	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 11

$26.00New observation · no comparable prior

OppenheimerSep 30

$80.00New observation · no comparable prior

$0$44.00$88.00

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Progress Phase 2 readout for TX45 and advance TX2100 into clinical developmentDirect metric needs a verified mapping
Limit operating losses while advancing clinical programsOperating income: $-24.218M
Maintain cash runway through late 2028 to fund operationsDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-47.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tectonic Therapeutic, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The multi-year view is still in a watch state: management has advanced key trials, but evidence of financial strength remains limited.

What's priced into Tectonic Therapeutic, Inc.

The snapshot provides no valuation or expectations data, so whether TECX is cheap or expensive versus peers cannot be assessed. The market’s assumptions are also unclear; confidence in this evidence is low.

What the fundamentals likely do

Near term, ongoing losses and weak recent performance leave TECX exposed to execution and industry risks, despite an August earnings beat following a May miss. Management reports lower quarterly losses and expense control, while cash declined but the stated runway extended to Q1 2029. Trial progress is tangible, but the next major evidence point is expected TX45 topline data in early Q1 2027.

What Tectonic Therapeutic, Inc. hinges on

The multi-year thesis depends on clinical progress, especially the TX45 results and continued development of TX2100, alongside enough cash to fund operations. Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strength among healthcare bellwethers could support the sector backdrop.